<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002250</url>
  </required_header>
  <id_info>
    <org_study_id>076A</org_study_id>
    <secondary_id>D0177g</secondary_id>
    <nct_id>NCT00002250</nct_id>
  </id_info>
  <brief_title>A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients With HIV-Associated Immune Thrombocytopenic Purpura</brief_title>
  <official_title>A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients With HIV-Associated Immune Thrombocytopenic Purpura</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To test the effectiveness of recombinant human CD4 Immunoglobulin G (CD4-IgG) in the&#xD;
      treatment of HIV-associated immune thrombocytopenic purpura in patients with all levels of&#xD;
      HIV infection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Immune Thrombocytopenic Purpura ( ITP )</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD4-IgG</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Dapsone at a constant dose level and only as a prophylaxis for Pneumocystis carinii&#xD;
             pneumonia (PCP).&#xD;
&#xD;
          -  Zidovudine (AZT) at a constant dose for the 12 weeks of treatment, except if&#xD;
             AZT-related toxicity is observed.&#xD;
&#xD;
        Patients must have the following:&#xD;
&#xD;
          -  HIV seropositive (asymptomatic, AIDS-related complex, or AIDS).&#xD;
&#xD;
          -  HIV-associated immune thrombocytopenic purpura.&#xD;
&#xD;
          -  The ability to sign a written informed consent form, which must be obtained prior to&#xD;
             treatment.&#xD;
&#xD;
          -  A willingness to abstain from all other experimental therapy for HIV infection during&#xD;
             the entire study period.&#xD;
&#xD;
          -  Patients currently on zidovudine are not excluded. However, the zidovudine dose level&#xD;
             must remain constant for 4 weeks prior to entry and for the 12 weeks of treatment,&#xD;
             except if zidovudine related toxicity is observed.&#xD;
&#xD;
          -  A life expectancy of at least 3 months.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Dapsone at a constant dose for more than 2 weeks prior to study entry.&#xD;
&#xD;
          -  Zidovudine at a constant dose for 4 weeks prior to study entry.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions and symptoms are excluded:&#xD;
&#xD;
          -  Active serious opportunistic infection (excluding positive block cultures of&#xD;
             Mycobacterium avium complex or Cytomegalovirus).&#xD;
&#xD;
          -  Malignancies other than Kaposi's sarcoma.&#xD;
&#xD;
          -  Tumor-associated edema.&#xD;
&#xD;
          -  Visceral Kaposi's sarcoma.&#xD;
&#xD;
          -  Significant neurologic, cardiac, or liver disease.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Ganciclovir (DHPG). Pyrimethamine. Clindamycin. Sulfadiazine. Folinic acid.&#xD;
             Prednisone. Intravenous gamma globulin. Intravenous acyclovir. Interferon. Systemic&#xD;
             corticosteroids. Non-steroidal anti-inflammatory drugs (NSAIDs). Known&#xD;
             immunomodulatory agents. Dideoxycytosine. Dideoxyinosine. Nucleoside analogs (with the&#xD;
             exception of zidovudine or topical acyclovir). Any experimental therapy.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Active serious opportunistic infection (excluding positive block cultures of&#xD;
             Mycobacterium avium complex or Cytomegalovirus).&#xD;
&#xD;
          -  Malignancies other than Kaposi's sarcoma.&#xD;
&#xD;
          -  Kaposi's sarcoma requiring therapy.&#xD;
&#xD;
          -  Tumor-associated edema.&#xD;
&#xD;
          -  Visceral Kaposi's sarcoma.&#xD;
&#xD;
          -  Significant neurologic, cardiac, or liver disease.&#xD;
&#xD;
          -  Conditions requiring excluded concomitant medications.&#xD;
&#xD;
          -  Herpes virus infection requiring intravenous acyclovir.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded for a minimum of 4 weeks prior to study entry:&#xD;
&#xD;
          -  Chemotherapy.&#xD;
&#xD;
          -  Immunomodulatory agents.&#xD;
&#xD;
          -  Any experimental therapy.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded for a minimum of 4 weeks prior to study entry:&#xD;
&#xD;
          -  Radiation therapy.&#xD;
&#xD;
          -  Any experimental therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>San Francisco Gen Hosp</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>941102859</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kahn J, Hassner A, Arri C, Coleman R, Kaplan L, Volberding P, Ammann A, Abrams D. A phase 1 study of recombinant human CD4 immunoglobulin g (rCD4-IgG) in patients with HIV-associated immune thrombocytopenic purpura. Int Conf AIDS. 1991 Jun 16-21;7(2):221 (abstract no WB2156)</citation>
  </reference>
  <verification_date>August 1991</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Recombinant Proteins</keyword>
  <keyword>IgG</keyword>
  <keyword>Drug Evaluation</keyword>
  <keyword>Antigens, CD4</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>CD4 Immunoadhesins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

